H5 n1 infection (avian influenza) – pipeline review, h1 2013 - Reports Corner

361 views
296 views

Published on

Global Markets Direct's, 'H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with latest updates, and special features on late-stage and discontinued projects.

https://www.reportscorner.com/reports/23245/H5N1-Infection-(Avian-Influenza)-%E2%80%93-Pipeline-Review,-H1-2013/

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
361
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
19
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

H5 n1 infection (avian influenza) – pipeline review, h1 2013 - Reports Corner

  1. 1. RC Reports Corner H5N1 Infection (Avian Influenza) – Pipeline Review, H1 2013
  2. 2. DescriptionDescription Reports Cornerwww.reportscorner.com Global Markets Direct's, 'H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with latest updates, and special features on late-stage and discontinued projects.
  3. 3. Brief SummaryBrief Summary Reports Cornerwww.reportscorner.com Global Markets Direct's, 'H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza). H5N1 Infection (Avian Influenza) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
  4. 4. Brief SummaryBrief Summary Reports Cornerwww.reportscorner.com Scope - A snapshot of the global therapeutic scenario for H5N1 Infection (Avian Influenza). - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
  5. 5. Brief SummaryBrief Summary Reports Cornerwww.reportscorner.com Reasons to buy - Identify and understand important and diverse types of therapeutics under development for H5N1 Infection (Avian Influenza). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding H5N1 Infection (Avian Influenza) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. .
  6. 6. Brief SummaryBrief Summary Reports Cornerwww.reportscorner.com - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  7. 7. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 H5N1 Infection (Avian Influenza) Overview 9 Therapeutics Development 10 An Overview of Pipeline Products for H5N1 Infection (Avian Influenza) 10 H5N1 Infection (Avian Influenza) Therapeutics under Development by Companies 12 H5N1 Infection (Avian Influenza) Therapeutics under Investigation by Universities/Institutes 16 Late Stage Products 17 Comparative Analysis 17 Mid Clinical Stage Products 18 Comparative Analysis 18
  8. 8. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Early Clinical Stage Products 19 Comparative Analysis 19 Discovery and Pre-Clinical Stage Products 20 Comparative Analysis 20 H5N1 Infection (Avian Influenza) Therapeutics – Products under Development by Companies 21 H5N1 Infection (Avian Influenza) Therapeutics – Products under Investigation by Universities/Institutes 25 Companies Involved in H5N1 Infection (Avian Influenza) Therapeutics Development 26 GlaxoSmithKline plc 26 Inovio Biomedical Corporation 27 Daiichi Sankyo Company, Ltd 28 Emergent BioSolutions Inc. 29 Generex Biotechnology Corporation 30 Celltrion, Inc. 31 Nanotherapeutics, Inc. 32 Novartis AG 33
  9. 9. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Vertex Pharmaceuticals Incorporated 34 CEL-SCI Corporation 35 OPKO Health, Inc. 36 Hemispherx Biopharma, Inc. 37 Intercell AG 38 Medicago Inc. 39 NanoViricides, Inc. 40 Medigen Biotechnology Corp. 41 CytoGenix, Inc. 42 XOMA Ltd. 43 Green Cross Corporation 44 Antigen Express, Inc. 45 Colby Pharmaceutical Company 46 LigoCyte Pharmaceuticals, Inc. 47 Adimmune Corporation 48
  10. 10. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com TechnoVax, Inc. 49 MacroGenics, Inc. 50 AlphaVax, Inc. 51 Vaxin, Inc. 52 REPLICor Inc. 53 Protein Sciences Corporation 54 VaxInnate Corporation 55 Obio Pharmaceutical Holdings Limited. 56 Canopus BioPharma Incorporated 57 iBio, Inc. 58 Sirnaomics, Inc. 59 ImmuneRegen BioSciences, Inc. 60 Inviragen, Inc. 61 PaxVax 62
  11. 11. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Denka Seiken Co., Ltd. 63 H5N1 Infection (Avian Influenza) – Therapeutics Assessment 64 Assessment by Monotherapy Products 64 Assessment by Combination Products 65 Assessment by Route of Administration 66 Assessment by Molecule Type 68 Drug Profiles 70 Homspera - Drug Profile 70 Flu Vaccine - Drug Profile 72 GelVac - Drug Profile 73 rintatolimod - Drug Profile 74 CEL-1000 - Drug VGX-3400X - Drug Profile 77 interferon alfa-n3 injection + interferon alfa-n3 low dose oral - Drug Profile 78 Pandemic Influenza Vaccine Patch - Drug Profile 79 REP-9-AC - Drug Profile 81
  12. 12. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com H5N1 Vaccine - Drug Profile 83 Vaccine For Pandemic Influenza (H1 & H5) - Drug Profile 85 PanBlok - Drug Profile 86 PanBlok - Drug Profile 88 PanBlok - Drug Profile 90 TG-21 - Drug Profile 92 Influenza Vaccine - Drug Profile 93 Aflunov - Drug Profile 95 H5N1 FCC Vaccine - Drug Profile 97 GSK-2340273A - Drug Profile 98 STP-702 - Drug Profile 101 VRC-AVIDNA036-00-VP - Drug Profile 102 F-10 Antibody Program - Drug Profile 103 TVX-003 - Drug Profile 104 CYDBA-507 - Drug Profile 105
  13. 13. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com (statin + caffeine) - Drug Profile 106 Influenza VLP vaccine - Drug Profile 107 MVA-H5HA - Drug Profile 108 Mult. mAbs/DARTs - Drug Profile 109 AE-AI Vaccine - Drug Profile 110 GSK-2590066A - Drug Profile 111 TMB-571 - Drug Profile 112 Flu Pandemic Vaccine - Drug Profile 113 GSK-1557484A - Drug Profile 115 Pandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) - Drug Profile 117 Flufirvitide-3 - Drug Profile 118 Anti-H5HA mAB - Drug Profile 119 H5N1 Avian Influenza Vaccine - Drug Profile 120 JVRS-100 + Pandemic Flu Vaccine - Drug Profile 122 PXVX-0103 - Drug Profile 124
  14. 14. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com MG-1109 - Drug Profile 125 INO-3510 - Drug Profile 127 INO-3401 - Drug Profile 129 AE-443p - Drug Profile 131 INO-3605 - Drug Profile 132 INO-3609 - Drug Profile 134 NV-INF-1 - Drug Profile 136 Avian Influenza Vaccine - Drug Profile 138 VAX-161 - Drug Profile 139 VX-787 - Drug Profile 140 Avian Flu Vaccine - Drug Profile 141 H5N1 Avian Influenza VLP vaccine + Glucopyranosyl Lipid A Adjuvant - Drug Profile 142 VAX161-01C - Drug Profile 144 AT-301 - Drug Profile 145 H5N1 Project - Drug Profile 146
  15. 15. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com KIB-PCI - Drug Profile 147 Chimigen Influenza Vaccine - Drug Profile 148 Antibody Against Avian Flu Virus - Drug Profile 149 rAd-04wtHA Vaccine - Drug Profile 150 rAd-04optHA Vaccine - Drug Profile 151Profile 75 rAd-04optHA + rAd-97optHA vaccine - Drug Profile 152 GP-1002 - Drug Profile 153 GREFLU/VIE - Drug Profile 154 H5N1 Infection (Avian Influenza) Therapeutics – Drug Profile Updates 155 H5N1 Infection (Avian Influenza) Therapeutics – Discontinued Products 173 H5N1 Infection (Avian Influenza) Therapeutics - Dormant Products 174 H5N1 Infection (Avian Influenza) – Product Development Milestones 176 Featured News & Press Releases 176 Appendix 184 Methodology 184
  16. 16. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Coverage 184 Secondary Research 184 Primary Research 184 Expert Panel Validation 184 Contact Us 185 Disclaimer 185
  17. 17. For more informationFor more information Reports Cornerwww.reportscorner.com For more information please visit our website https://www.reportscorner.com/reports/23245/H5N1-Infection-(Avian-Influenza)- %E2%80%93-Pipeline-Review,-H1-2013/
  18. 18. Reports Corner Thank YouThank You www.reportscorner.com RC Contact us: contact@reportscorner.com

×